Psychiatry and Neurology, Neurology · Hawthorne, NY
NPI
1437318573
Since 2008
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
19 Bradhurst Ave, Suite 2850
Hawthorne, NY, 10532
Phone (914) 345-1313
Groups this clinician bills Medicare through
Medicare paid, 2024
$109K
8,826 services
Medicare patients, 2024
307
Average age 73
Drug cost, 2024
$2.3M
2,628 prescriptions
Company payments, 2025
$32K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert Fekete was code J0585 (injection, onabotulinumtoxina, 1 unit), 8,100 times for 14 patients. In total Robert Fekete billed 8,826 services in 19 codes, and Medicare paid $109K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 8,100 | 14 | $4.92 | $40K |
| 99214 Office E&M - Established | Office | 378 | 198 | $104.81 | $40K |
| 99232 Hospital E&M - Subsequent | Facility | 47 | 28 | $67.52 | $3,173 |
| 99205 Office E&M - New | Office | 44 | 44 | $192.04 | $8,450 |
| 99223 Hospital E&M - Initial | Facility | 34 | 32 | $146.34 | $4,976 |
| 99215 Office E&M - Established | Office | 12 | 12 | $161.33 | $1,936 |
By year: 2022 $120K for 8,277 services; 2023 $125K for 10,436 services; 2024 $109K for 8,826 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robert Fekete prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 591 prescriptions and refills. In total Robert Fekete wrote 2,628 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 591 | 1,218 | 141 | $19K |
| Propranolol Hcl Generic | 143 | 306 | 47 | $2,157 |
| Primidone Generic | 106 | 201 | 24 | $2,795 |
| Amantadine Amantadine Hcl | 103 | 195 | 29 | $4,625 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 94 | 194 | 24 | $7,122 |
| Rytary Carbidopa/Levodopa | 92 | 191 | 25 | $118K |
| Nuplazid Pimavanserin Tartrate | 76 | 92 | Under 11 | $427K |
| Nourianz Istradefylline | 72 | 76 | 11 | $153K |
| Rasagiline Mesylate Generic | 62 | 124 | 14 | $13K |
| Gabapentin Generic | 54 | 108 | 16 | $1,083 |
| Ingrezza Valbenazine Tosylate | 52 | 52 | Under 11 | $406K |
| Selegiline Hcl Generic | 44 | 62 | Under 11 | $4,054 |
| Gocovri Amantadine Hcl | 44 | 52 | Under 11 | $115K |
| Quetiapine Fumarate Generic | 43 | 91 | 16 | $1,690 |
| Inbrija Levodopa | 39 | 39 | Under 11 | $125K |
Brand drugs: 657 claims; generic drugs: 1,971 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert Fekete $32K ($32K in general payments such as food, travel and fees) from 9 companies. The largest payer was Neurocrine BioSciences, Inc. with $16K.
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. NBIX | 20 | $16K |
| Teva Pharmaceuticals USA, Inc. TEVA | 2 | $9,096 |
| ACADIA Pharmaceuticals Inc ACAD | 13 | $3,978 |
| MDD US Operations, LLC | 6 | $2,046 |
| Medtronic, Inc. MDT | 1 | $156 |
| Kyowa Kirin, Inc. 4151.T | 1 | $137 |
| Abbott Laboratories ABT | 1 | $135 |
| Abbvie Inc. ABBV | 3 | $91.13 |
| Merz Pharmaceuticals, LLC | 1 | $42.86 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.